Immunome
IMNM
28 hedge funds and large institutions have $4.85M invested in Immunome in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
17% more funds holding
Funds holding: 24 → 28 (+4)
0% more call options, than puts
Call options by funds: $6K | Put options by funds: $6K
2.41% less ownership
Funds ownership: 19.73% → 17.32% (-2.4%)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
52% less capital invested
Capital invested by funds: $10.1M → $4.85M (-$5.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$88.9K |
| 2 |
N
Natixis
Paris,
France
|
+$44.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$9.38K |
| 5 |
BlackRock
New York
|
+$2.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
-$1.18M |
| 2 |
Neuberger Berman Group
New York
|
-$86K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$59.6K |
| 4 |
Cerity Partners
New York
|
-$14.6K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NFSG
26
Newbridge Financial Services Group
Boca Raton,
Florida
| $829 | – | – | – |
|
|
FFA
27
Farther Finance Advisors
San Francisco,
California
| $221 | +$403 | +100 | New |
|
28
Bank of America
Charlotte,
North Carolina
| $24 | +$44 | +11 | New |
|
|
29
Neuberger Berman Group
New York
| – | -$86K | -19,444 | Closed |
|
30
BNP Paribas Financial Markets
Paris,
France
| – | -$297 | -67 | Closed |
|
IMNM Hedge Fund Activity: Q4 2022 in Review
28 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q4 2022, worth a combined $4.85M — down 52% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IMNM positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $88.9K. The largest seller was Prentice Capital Management, cutting an estimated $1.18M.
- 28 institutional investors held Immunome (IMNM) as of Q4 2022, up from 24 in Q3 2022.
- Funds reported $4.85M of Immunome stock for Q4 2022, down 52% quarter-over-quarter.
- 6 funds opened new Immunome positions in Q4 2022 and 2 closed out, a net change of +4 holders.
- The largest Immunome buyer in Q4 2022 was Susquehanna International Group, an estimated $88.9K added.
- The largest Immunome seller in Q4 2022 was Prentice Capital Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q4 2022.